Urgent.News

What's breaking now, across hundreds of outlets.

Finance & Markets

Nuvectis: 3 Key Takeaways for Long-Term Investors

A once-daily PNH candidate and a brain-penetrant cancer drug both hinge on the regulatory path ahead, which is still unfolding.

1. Nuvectis announces its transition to a late-stage clinical drug developer after securing licensing rights for two promising drug candidates, NXP-100 and NXP-200, which expand its oncology and rare disease pipeline.

2. The company received $140 million in cash, providing operational stability through the second half of 2029, enabling it to pursue multiple value inflection points in its pipeline.

3. NXP-100, a lead candidate, treats paroxysmal nocturnal hemoglobinuria (PNH) with once-daily oral dosing, offering a potential advantage over existing twice-daily alternatives, such as FABALTA. NXP-200 targets mutated solid tumors, showing complete responses in patients with recurrent high-grade glioma, including those with prior therapy exposure.

Rewritten by urgent.news; may contain errors — check the original.

Sources: fool.com · nasdaq.com

Also reported by 1 other outlet

Every outlet that reported this, and when →

Read the original at fool.com →

Report a problem with this story

More in Finance & Markets

More from Sunday 22 November →